These developments were a major success, largely because of a computers ability to compare combinations of drugs and see what their additive effect might be on the outcome of the disease.
This is very useful for a complex disease such as Fragile X. For example, if there are 500 drugs for which gene expression profiles could be collected and the software could combine them in groups of 2, it would produce 250,000 different combinations. This is what Healx did with 4,280 different monotherapies, resulting in 9,157,069 potential therapies. The computers sorted through them and found 18 combinations which could be effective, 8 of them altered 4 major symptoms and all were tested in mouse models for safety and efficacy.
The 3 best options are now being taken by Healx into clinical trials with close consultation with FRAXA.